A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99

Authors:
  • GLG. L. Lemma
    G. L. Lemma
  • PLP. J. Loehrer
    P. J. Loehrer
  • JLJ. W. Lee
    J. W. Lee
  • CLC. J. Langer
    C. J. Langer
  • WTW. J. Tester
    W. J. Tester
  • DJD. H. Johnson
    D. H. Johnson

Abstract
8018 Background: Thymoma (THY) and thymic carcinoma (TC) are the most common tumors of the anterior mediastinum. Anthracycline-based combination chemotherapies have yielded response rates ranging from 50–90% in previously untreated patients (pts). The primary endpoint of this trial was to evaluate the objective response rate of paclitaxel plus carboplatin in previously untreated pts with advanced THYor TC. Secondary endpoints include the duration of response and toxicity for this regimen. Methods: Patients (pts) with histologically proven, unresectable THY or TC, PS <2, without prior systemic chemotherapy for thymic malignancies were eligible. Pts were treated with carboplatin (AUC = 5) plus paclitaxel (225 mg/m2) every 3 weeks for a maximum of six cycles of therapy. Results: From February, 2001 to December, 2007, 46 pts were enrolled (THY= 25; TC= 21). One pt was ineligible and never received therapy ( in THY). All treated pts were included in the toxicity analysis and all eligible were included in the s...